SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token $HMMM is gaining attention, with many users discussing its potential and availability on Phantom Wallet. Community members are using terms like "rocket," "moon," and "gem" to describe the token's momentum. Some users are also speculating about the driving forces behind the recent price action.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending as traders discuss its potential Coinbase listing and the impact on its price. The community is focused on its limited supply of 1 million coins, speculating on possible price movements and 

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction as a community-driven token with viral hype, trending on Stocktwits with serious volume. The community emphasizes its strength and unity, rallying behind upcoming events like Karolina Arm's sponsored fight. Discussions highlight $SLAP's ambition to become a global brand, transcending its meme origins through real-world partnerships and a dedicated community.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as community members discuss its potential in the expanding play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Conversations highlight the growing community, new exchange listings, and its potential within the AI and blockchain space. Some traders are also taking profits from other tokens and moving them into Virtual Protocol.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community debates its future following FDA approval of Tonmya, with discussions focused on potential sales, upcoming catalysts, and whether the stock is undervalued. Some traders express frustration with management and the stock's performance, while others remain optimistic about long-term growth and potential short squeezes. BlackRock's increased stake is being viewed as a potential bullish signal amid the ongoing volatility.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and circulating supply, anticipating a potential breakout. Some community members point to its integration with Aleph Zero, while others speculate about possible listings on major exchanges like Binance as a catalyst for significant gains. Technical analysis chatter includes mentions of oversold RSI conditions and bull flag formations.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to news of a potential shakeup in the Alzheimer's space following a recent investment in Vanqua Bio, which has investors speculating about Biogen's strategy around C5aR1 inhibitors, a target also being pursued by InflaRx ($IFRX). The community is analyzing the implications of Biogen's move for InflaRx's valuation and potential acquisition, viewing it as both mechanistic validation and a catalyst for sentiment. There is also discussion around Biogen's earnings and growth prospects, especially concerning new therapies offsetting multiple sclerosis portfolio weakness.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

Columbus Circle Capital ($BRR) is trending as the community discusses Eric Jackson joining the board and anticipates a potential pump, drawing comparisons to past option surges. Chatter revolves around upcoming call options and a proposed merger with ProCap BTC, with some seeing a potentially favorable risk-reward scenario due to the SPAC's NAV floor. Recent news includes updates to the merger agreement and the appointment of a new CFO.

Codatta

Codatta ($XNY) is trending as the community discusses its potential breakout, with some suggesting it's building towards a significant move. Many traders are watching its correlation with Bitcoin ($BTC), anticipating a surge if $BTC breaks resistance. Technical analysis is being shared, highlighting bullish formations and key support levels.

KraneShares Trust - KraneShares Global Humanoid and Embodied Intelligence Index ETF

KraneShares Global Humanoid and Embodied Intelligence Index ETF

$KOID is trending as discussions emerge around robotics and AI, specifically humanoid robots. Community members are actively comparing $KOID to other robotics ETFs and discussing the potential impact of Chinese investment in the sector, with some noting the fund's growing exposure and potential for long-term growth. Mentions of Elon Musk's views on robotics and humanoid development are also contributing to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor...

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced that additional data from the ABACUS-1 trial has been...

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ('Kiora' or...

Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 3.8%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX  Get Free Report) dropped 3.8% during mid-day trading on Thursday . The company traded as low as $0.58 and last traded at $0.58. Approximately 78,144...

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced the publication of results from a Phase 1 double-masked...

HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know

Latest Ratings for KPRX
 DateFirmActionFromTo Jan 2022Maxim GroupInitiates Coverage OnBuy
 View More Analyst Ratings for KPRX

 View the Latest Analyst Ratings

read more...

Kiora Pharmaceuticals price target lowered by $1.50 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million...

Kiora Pharmaceuticals Inc trading resumes

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Kiora Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$2.56
Prev Close	$2.54
Open	$2.55
Dividend Yield	0.00%
50-Day Moving Average	$2.68
Beta	0.55
Avg. Volume	33,340.81
PE Ratio	-0.78

52-Week High	$4.18
52-Week Low	$2.21
Market Capitalization	$8.79M
EPS (Annual)	$0.8714
Price to Book	0.40
Revenue Per Employee	$1.33M
Enterprise Value/EBITDA	N/A

KPRX
Kiora Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KPRX News

KPRXKiora Pharmaceuticals Inc